Rimonabant - Wikipedia

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn ...

Acomplia: Uses, Dosage, Side Effects & Warnings - Drugs.com

Sanofi-Aventis has withdrawn rimonabant from the market globally and it is no longer under development. 1 Acomplia was officially withdrawn by the European Medicines ...

Acomplia (Rimonabant) – Investigational Agent for the ...

Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works...Read More...

an Buy Rimonabant | Cannabinoid Receptor antagonist ...

Rimonabant (SR141716) is the first selective and orally active antagonist of the central brain cannabinoid receptor (CB1) with IC50 with 13.6 nM and EC50 with 17.3 nM ...

European Medicines Agency - Find medicine - Acomplia

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Rimonabant | C22H21Cl3N4O - PubChem - The PubChem Project

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1.

Rimonabant – Wikipedia

Rimonabant ist ein Arzneistoff, der als Appetitzügler zur Behandlung des Übergewichts eingesetzt wurde, eigentlich allerdings zur Raucherentwöhnung von dem ...

Rimonabant — Wikipédia

Le rimonabant (ou SR141716) est un médicament anorexigène contre l'obésité agissant comme un agoniste inverse des récepteurs cannabinoïdes CB1.

リモナバン - Wikipedia

リモナバン（リモナバント, 英語: Rimonabant, SR141716）は、選択的な カンナビノイド受容体タイプ1 （英語版） の拮抗薬で ...

Rimonabant - Wikipedia

Rimonabant (merknaam: Acomplia®) is een inmiddels verboden geneesmiddel dat aangrijpt op een van de twee soorten bekende receptoren voor cannabinoïden, CB1.